Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients

Abstract Background Metastatic melanoma is an aggressive form of skin cancer with a high mortality rate and the fastest growing global incidence rate of all malignancies. The introduction of BRAF/MEK inhibitor combinations has yielded significant increases in PFS and OS for melanoma. However, at pre...

Full description

Bibliographic Details
Main Authors: Adil Daud, Japinder Gill, Sheily Kamra, Lei Chen, Amit Ahuja
Format: Article
Language:English
Published: BMC 2017-01-01
Series:Journal of Hematology & Oncology
Subjects:
Dabrafenib
Trametinib
Vemurafenib
Cobimetinib
Metastatic melanoma
Indirect treatment comparison
Online Access:http://link.springer.com/article/10.1186/s13045-016-0369-8

Internet

http://link.springer.com/article/10.1186/s13045-016-0369-8

Similar Items